A big week for the Huntington's field with 2 significant bodies of work from leading labs publishing in Cell and Nature.
We believe that the imperative to treat Huntington's disease (and other triplet disorders) with therapies which can slow down somatic expansion, the process which drives disease, with the potential to materially delay onset of symptoms, is now firmly established.
Our commitment and excitement about taking forwards our FAN1 upregulation programme could not be higher!
Read the full paper here.